Skip to main content
Fanli Digital Technology Co., Ltd logo

Fanli Digital Technology Co., Ltd — Investor Relations & Filings

Ticker · 600228 ISIN · CNE000000Y78 Shanghai Stock Exchange Telecommunications, computer programming, consultancy, computing infrastructure, and other information service activities
Open in API
Filings indexed 2,248 across all filing types
Latest filing 2020-09-17 M&A Activity
Country CN China
Listing Shanghai Stock Exchange 600228

About Fanli Digital Technology Co., Ltd

https://corp.fanli.com/

Fanli Digital Technology Co., Ltd. provides e-commerce integration and digital marketing services. The company operates a comprehensive platform that connects consumers with various online retail ecosystems through value-added services such as cash-back rewards, discount coupons, and promotional insights. Its core business model focuses on performance-based marketing, utilizing data-driven strategies to facilitate sales conversions for brand partners. Key offerings include brand promotion, user loyalty management, and targeted advertising solutions. By integrating diverse shopping channels into a single interface, the company optimizes the consumer purchasing journey and provides brands with scalable traffic acquisition tools. The platform serves as a strategic intermediary, leveraging user behavioral data to enhance marketing efficiency and provide measurable returns for merchants while delivering cost savings to a broad user base.

Recent filings

Filing Released Lang Actions
收购报告书摘要（上海享锐、上海鹄睿）
M&A Activity Classification · 100% confidence The document is titled as a "收购报告书摘要" which translates to "Acquisition Report Summary". It contains detailed information about the acquirer, the target company, shareholding structures, legal references to Chinese securities laws, and the acquisition plan. The content includes descriptions of the acquisition decision, purpose, and related agreements. This type of document is typically related to merger and acquisition activities. It is not a full annual or interim report, nor an earnings release or regulatory filing. It is a detailed acquisition report, which fits the category of M&A Activity (TAR). The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the correct classification is M&A Activity (TAR).
2020-09-17 Chinese
重大资产置换、发行股份及支付现金购买资产并募集配套资金暨关联交易报告书（草案）与预案（修订稿）差异情况对比表
Regulatory Filings Classification · 95% confidence The document is titled as a comparison table between a draft report and a revised plan related to a major asset swap, share issuance, cash payment for asset purchase, and related party transactions by Jiangxi Changjiu Bio-chemical Co., Ltd. It references board meetings, regulatory inquiry letters from the Shanghai Stock Exchange, and detailed sections covering transaction overview, company financial data, transaction counterparties, asset details, evaluation, issuance of shares, contract contents, compliance analysis, management discussion, financial accounting information, related party transactions, risk factors, and opinions from independent directors and intermediaries. The document is 3876 characters long, which is relatively short and appears to be a summary or comparison table rather than the full report itself. It does not contain full financial statements or comprehensive financial analysis but rather highlights differences between two versions of a transaction report and related disclosures. This fits the profile of a Regulatory Filing (RNS) as it is a regulatory disclosure document related to a major transaction, but not the full transaction report or financial report itself. It is not an announcement of report publication (RPA) because it contains substantive content comparing two documents. It is not a Capital/Financing Update (CAP) because it is more comprehensive and regulatory in nature. Therefore, the best classification is Regulatory Filings (RNS).
2020-09-17 Chinese
华泰联合证券有限责任公司关于江西昌九生物化工股份有限公司本次重组摊薄即期回报及采取填补措施之独立财务顾问核查意见
Audit Report / Information Classification · 95% confidence The document is an independent financial advisor's verification opinion regarding the dilution of immediate returns and remedial measures related to a major asset restructuring of Jiangxi Changjiu Biochemical Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission (CSRC) and other government opinions related to capital market investor protection and asset restructuring. The content includes detailed financial impact analysis, assumptions, and commitments by the company and its controlling shareholders to prevent dilution of immediate returns. The document is a standalone advisory opinion focused on the audit and verification of financial and regulatory compliance aspects of the restructuring, rather than a full annual or interim financial report. It does not contain comprehensive financial statements or quarterly results but rather a specialized audit-related opinion on a specific transaction and its financial implications. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 4370 characters, which is sufficient for a detailed advisory opinion but not a full annual or interim report. It is not a simple announcement or certification, so it is not RNS or RPA. Hence, the classification is AR with high confidence. FY 2020
2020-09-17 Chinese
华泰联合证券有限责任公司在充分尽职调查和内核基础上出具的承诺
Capital/Financing Update Classification · 90% confidence The document is a statement from an independent financial advisor (华泰联合证券有限责任公司) regarding their due diligence and professional opinion on a major asset restructuring and related transactions of 江西昌九生物化工股份有限公司. It references compliance with regulatory rules for major asset restructuring and issuance of shares, and confirms the independence and thoroughness of the advisor's work. The document is a formal commitment letter or opinion letter from the financial advisor rather than a full report or announcement of financial results. It does not contain financial statements or detailed financial data, nor is it a shareholder meeting material or voting result. It is not a regulatory filing or certification letter either, but a professional opinion related to a transaction. This type of document is best classified under Capital/Financing Update (CAP) as it relates to a major asset transaction and financing activities with an independent advisor's opinion.
2020-09-17 Chinese
华泰联合证券有限责任公司出具关于江西昌九生物化工股份有限公司本次重大资产重组前业绩异常或本次重组存在拟置出资产情形相关事项的专项核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed independent financial advisor's special investigation opinion related to a major asset restructuring of Jiangxi Changjiu Bio-chemical Co., Ltd. It includes extensive information on compliance with regulatory requirements, fulfillment of public commitments, recent three-year operational compliance, absence of illegal fund occupation or illegal external guarantees, administrative penalties, and audit reports. The document references regulatory guidelines from the China Securities Regulatory Commission and includes audit reports and detailed financial and compliance analysis over multiple years. It is not a brief announcement or a simple certification but a comprehensive investigative report on the company's financial and regulatory status in relation to a major asset restructuring. This fits the definition of an Audit Report / Information (AR) as it is a standalone audit-related report focusing on compliance, audit findings, and regulatory adherence, distinct from a full Annual Report or other categories. H1 2020
2020-09-17 Chinese
华泰联合证券有限责任公司关于江西昌九生物化工股份有限公司本次交易产业政策和交易类型之独立财务顾问核查意见
Capital/Financing Update Classification · 95% confidence The document is an independent financial advisor's verification opinion regarding a major asset swap, issuance of shares, cash purchase of assets, and related party transaction involving Jiangxi Changjiu Biochemical Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission (CSRC) and stock exchange rules related to mergers and acquisitions, asset restructuring, and issuance of shares. The document includes detailed analysis of the transaction type, industry classification, and compliance with relevant policies. It is a specialized advisory opinion on a significant corporate transaction, not a general annual or quarterly report, earnings release, or proxy statement. The document length is under 5,000 characters but contains substantive content and detailed financial and regulatory analysis, so it is not a mere announcement or certification. The content aligns with a Capital/Financing Update (CAP) as it discusses issuance of shares, asset acquisition, and fundraising related to a major transaction. Therefore, the appropriate classification is CAP with high confidence.
2020-09-17 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.